Chicago, IL: The contents of hemp-derived cannabinoid products seldom match the information advertised on the products’ labels, according to a laboratory analysis conducted by the University of Chicago.
Of the 17 different hemp-derived flower products analyzed, fifteen contained lesser quantities of advertised cannabinoids (e.g., delta-8 THC, delta-10 THC, CBD). One sample contained no detectable level of cannabinoids.
Of the eight edible products analyzed, three contained no detectable levels of advertised cannabinoids. One product contained lower levels of advertised cannabinoids, while three contained higher quantities.
The findings are consistent with those of other studies reporting discrepancies in the contents of unregulated hemp-derived products.
“Most of the edible and plant cannabinoid products do not match their packaging and labeling,” the study’s author concluded. “This, in conjunction with the absence of regulations and safety testing, is a cause for concern for public safety as people (and minors) consume these products.”
Delta-8 THC and other cannabinoids present in commercially available hemp-derived products are typically produced following a chemical synthesis. Those engaged in manufacturing these products are not regulated and may use potentially dangerous household products to facilitate this process. Lab analyses of these unregulated products have repeatedly found that they contain lower levels of cannabinoids than what is advertised on the products’ labels. Some products have also been found to possess heavy metal contaminants and unlabeled cutting agents.
In 2022, NORML issued a report on delta-8 THC and other novel, synthetically derived cannabinoids that cautioned consumers to avoid these unregulated products because they are untested and may contain impurities.
The full text of the study, “The public safety risk of hemp products sold at unlicensed retailers,” appears in the Journal of Toxicology Current Research. Additional information is available in the NORML Fact Sheet, ‘NORML’s Guide to Delta-8 THC and Other Novel Cannabinoids.‘